Claims for Patent: 11,241,549
✉ Email this page to a colleague
Summary for Patent: 11,241,549
| Title: | Dry powder inhaler and system for drug delivery |
| Abstract: | A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide. |
| Inventor(s): | Smutney Chad C., Kinsey P. Spencer, Sahi Carl R., Adamo Benoit, Polidoro John M., McLean Scott, Overfield Dennis, Bryant Anthony |
| Assignee: | MannKind Corporation |
| Application Number: | US16271585 |
| Patent Claims: |
Details for Patent 11,241,549
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | January 15, 1974 | ⤷ Start Trial | 2039-02-08 |
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | December 27, 1984 | ⤷ Start Trial | 2039-02-08 |
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | February 15, 1985 | ⤷ Start Trial | 2039-02-08 |
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | February 16, 1990 | ⤷ Start Trial | 2039-02-08 |
| Bel-mar Laboratories, Inc. | CHORIONIC GONADOTROPIN | chorionic gonadotropin | Injection | 017054 | March 26, 1974 | ⤷ Start Trial | 2039-02-08 |
| Ferring Pharmaceuticals Inc. | A.P.L. | chorionic gonadotropin | For Injection | 017055 | December 13, 1974 | ⤷ Start Trial | 2039-02-08 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch